genom
sequenc
sever
blood
born
respiratori
virus
recent
recov
directli
clinic
specimen
variant
techniqu
known
sequenceindepend
singl
primer
amplif
relat
method
increasingli
use
search
caus
diseas
presum
infecti
aetiolog
agent
yet
found
method
requir
prior
knowledg
genom
sequenc
viru
may
present
patient
specimen
includ
whole
genom
amplif
random
pcr
subtract
hybridis
differenti
display
review
consid
develop
applic
techniqu
sinc
earli
viral
genom
recov
molecular
biolog
method
clinic
specimen
sequenc
subsequ
deduc
tabl
often
first
step
characteris
previous
unknown
virus
led
express
viral
protein
use
diagnost
assay
eg
eia
even
growth
viru
cell
cultur
molecular
clone
eg
hcv
genom
virus
discov
molecular
method
divers
encompass
almost
full
rang
rna
dna
singl
doubl
strand
segment
linear
circular
tabl
first
method
devis
invent
pcr
rang
simpl
clone
parvoviru
recombin
cdna
librari
construct
hcv
advent
pcr
primer
base
conserv
region
viral
genom
eg
polymeras
gene
design
amplifi
sequenc
novel
virus
exampl
retrovirus
degener
consensu
primer
gener
use
search
specif
sort
viru
genom
sever
relat
pcr
method
develop
involv
first
ligat
primer
bind
site
known
adapt
linker
oligonucleotid
dna
fragment
second
sequenc
enrich
amplif
two
well
known
method
represent
differ
analysi
rda
sequenceindepend
singl
primer
amplif
sispa
although
rda
success
use
discov
least
three
virus
sispatyp
method
popular
last
year
tabl
review
discuss
method
other
attempt
show
may
use
appli
previou
review
subject
muerhoff
colleagu
sispa
sispa
introduc
rey
et
al
techniqu
identifi
viral
nucleic
acid
unknown
sequenc
present
low
concentr
use
amplifi
cdna
prepar
mg
nucleic
acid
extract
g
faecal
sampl
clone
immunoscreen
sisparecov
dna
led
first
sequenc
noroviru
genom
also
astroviru
later
use
recoveri
hepat
g
viru
genom
initi
describ
sispa
procedur
similar
previous
publish
method
clone
cellular
mrna
chromosom
dna
one
method
figur
describ
akowitz
manuelidi
refer
primerdirect
enzymat
amplif
develop
make
cdna
librari
small
amount
mrna
dna
linkeradapt
gener
anneal
togeth
complementari
oligonucleotid
ligat
blunt
end
cdna
phosphoryl
end
increas
effici
ligat
dna
strand
could
coval
join
togeth
phosphodiest
bond
oligonucleotid
complementari
end
ligat
cdna
could
use
primer
pcr
amplif
way
repres
bacteriophag
cdna
librari
creat
pg
globin
mrna
anoth
method
figur
describ
johnson
figur
linkeradapt
overhang
one
phosphoryl
end
synthet
oligonucleotid
use
work
akowitz
manuelidi
oligonucleotid
expos
kinas
add
group
anneal
oligonucleotid
make
adapterlink
adapt
anneal
bluntend
cdna
cdna
contain
region
interest
whose
sequenc
unknown
oligonucleotid
use
pcr
primer
amplifi
cdna
abl
anneal
end
cdna
attach
adapterslink
group
oligonucleotid
intend
increas
effici
ligat
linkeradapt
cdna
dna
strand
could
coval
join
togeth
phosphodiest
bond
figur
ligat
linkeradapt
overhang
restrict
site
dna
digest
restrict
enzym
strategi
johnson
amplifi
fragment
chromosom
dna
digest
mboi
ligat
mboi
linkeradapt
dna
initi
chromosom
dna
unknown
sequenc
digest
restrict
enzym
mboi
linker
adapt
made
oligonucleotid
end
oligonucleotid
expos
kinas
add
phosphat
group
effici
ligat
linkeradaptor
ligat
onto
mboi
digest
chromosom
dna
oligonucleotid
subsequ
use
primer
pcr
amplifi
chromosom
dna
unknown
sequenc
involv
digest
chromosom
dna
restrict
enzym
mboi
linkeradapt
overhang
mboi
site
made
complementari
pair
oligonucleotid
complementari
adapt
ligat
mboi
digest
chromosom
dna
oligonucleotid
subsequ
use
pcr
primer
origin
formul
sispa
figur
use
element
method
involv
direct
ligat
asymmetr
adapt
refer
linkerprim
origin
paper
onto
termini
bluntend
cdna
common
end
sequenc
adapt
allow
cdna
amplifi
subsequ
pcr
use
singl
primer
restrict
enzym
site
ecori
noti
includ
within
linker
dna
gener
pcr
amplif
could
clone
vector
use
site
subsequ
easili
sequenc
addit
primer
half
nrui
site
adapt
ligat
togeth
form
dimer
could
remov
digest
enzym
nrui
nrui
digest
would
leav
bluntend
termini
adapt
phosphat
group
need
therefor
oligonucleotid
phosphat
group
ad
enzym
polynucleotid
kinas
use
procedur
previous
describ
year
later
lambden
clark
develop
sispa
methodolog
dsrna
virus
figur
demonstr
feasibl
method
use
human
rotaviru
group
c
genom
segment
base
pair
oligonucleotid
ligat
onto
dsrna
segment
block
end
amino
group
phosphoryl
end
rna
strand
separ
ssrna
revers
transcrib
cdna
amplifi
pcr
complementari
primer
method
variat
subsequ
use
recoveri
variou
rotaviru
genom
clinic
sampl
recent
year
sispa
develop
amplifi
singl
doublestrand
rna
dna
heterogen
size
sequenc
figur
give
overview
techniqu
initi
need
pretreat
sampl
remov
nonvir
nucleic
acid
might
come
bacteria
host
nuclei
mitochondria
method
use
separ
viral
nonvir
nucleic
acid
base
rel
small
size
viral
particl
protect
viral
genom
capsid
present
envelop
exampl
purif
rotaviru
dsrna
faec
lambden
et
al
treat
faecal
suspens
ribonucleas
prior
extract
guanidiniumbas
reagent
rnazol
b
silica
particl
geneclean
ii
high
concentr
rotaviru
present
faec
eg
particl
facilit
extract
ng
dsrna
recov
virus
tissu
may
yield
much
genom
nucleic
acid
remov
extran
dna
rna
becom
even
critic
extract
viral
nucleic
acid
blood
alland
et
al
purifi
serum
mm
filter
remov
cell
mitochondria
remov
free
dna
digest
dnase
virus
larger
mm
exampl
herpesvirus
caesium
chlorid
gradient
densiti
ligat
cdna
unknown
sequenc
overlap
one
end
hybrid
ensur
blunt
end
adapt
ligat
blunt
end
cdna
adapt
contain
ecori
noti
restrict
site
amplifi
dna
could
insert
clone
vector
effici
due
sequenc
size
restrict
site
ecori
noti
enzym
cut
dna
infrequ
unlik
occur
often
cdna
henc
site
commonli
engin
clone
vector
adapt
contain
half
nrui
site
blunt
end
therefor
two
adapt
ligat
togeth
form
dimer
nrui
site
form
digest
nrui
prior
ligat
cleav
dimer
back
two
monom
step
necessari
dimer
may
preferenti
ligat
clone
vector
reduc
effici
cdna
clone
rey
et
al
figur
overview
sispa
method
use
amplifi
viral
nucleic
acid
unknown
sequenc
initi
sampl
pretreat
combin
method
aid
purif
viral
nucleic
acid
method
includ
filtrat
sampl
remov
host
cell
mitochondria
remov
extracellular
dna
dnase
treatment
isol
viral
particl
centrifug
final
remain
viral
nucleic
acid
purifi
silica
particl
guanidinium
extract
method
sampl
may
need
divid
stage
known
whether
viral
nucleic
acid
either
rna
dna
ssdna
present
second
strand
dna
need
synthes
sampl
contain
rna
cdna
need
gener
dsdna
produc
digest
restrict
enzym
enabl
ligat
adapterlink
relev
overhang
altern
adapterlink
blunt
end
ligat
onto
termini
undigest
dsdna
amplifi
unknown
viral
nucleic
acid
primer
use
complementari
known
sequenc
adapterlink
select
round
amplif
perform
use
primer
addit
nucleotid
end
theori
quarter
dna
fragment
amplifi
final
sequenc
amplifi
viral
nucleic
acid
characteris
downstream
clone
sequenc
detail
method
found
main
text
viru
particl
usual
exce
gml
sucros
cushion
usual
could
give
higher
yield
filtrat
anoth
option
prior
extract
concentr
viral
particl
ultracentrifug
case
may
possibl
use
cell
cultur
amplifi
viru
present
cell
show
cytopath
effect
nucleic
acid
extract
viru
purifi
cultur
supernat
viral
nucleic
acid
extract
either
commerci
kit
eg
qiagen
crawley
uk
chaotrop
agent
trizol
invitrogen
paisley
uk
sometim
necessari
divid
sampl
stage
possibl
contain
unknown
rna
dna
virus
necessari
gener
dsdna
viral
nucleic
acid
start
molecul
sispa
rna
virus
cdna
gener
via
revers
transcriptas
reaction
altern
revers
transcript
may
incorpor
part
sispa
reaction
ssdna
viru
suspect
exampl
parvovirus
packag
negativestrand
dna
circovirus
ssdna
circular
genom
secondstrand
dna
synthesi
reaction
need
incorpor
major
sispa
method
fragment
dsdna
restrict
enzym
adapt
ligat
viral
genom
limit
genom
complex
restrict
enzym
four
base
pair
recognit
site
use
exampl
csp
msei
howev
viral
genom
exampl
ecori
may
appropri
adapt
design
minim
selfcomplementari
sequenc
gc
bia
specif
anneal
reaction
may
contain
restrict
enzym
site
downstream
clone
adapt
either
design
bluntend
ligat
overhang
complementari
restrict
enzym
use
fragment
viral
dna
prevent
concatameris
adapt
aminolink
phosphoryl
one
end
mention
ligat
adapt
dsdna
unknown
sequenc
amplifi
pcr
use
primer
complementari
known
adapt
sequenc
due
low
complex
viral
genom
restrict
digest
produc
larg
amount
limit
number
fragment
amplif
visibl
discret
band
agaros
gel
larger
human
bacteri
genom
complex
viral
genom
therefor
mani
differ
size
fragment
gener
restrict
digest
amplif
fragment
would
result
dna
smear
agaros
gel
ultim
result
viral
pcr
amplicon
either
clone
sequenc
immunoscreen
characteris
hybridis
reaction
identifi
via
dna
microarray
main
advantag
sispa
use
identifi
unknown
viral
nucleic
acid
present
rel
limit
amount
copi
ii
cultur
independ
method
appli
kind
clinic
sampl
use
identifi
ss
dsrna
dna
virus
abund
host
mitochondri
dna
sampl
main
disadvantag
also
presenc
contamin
sequenc
eg
bacteri
one
monitor
extract
nucleic
acid
screen
pcr
human
rdna
human
mitochondri
dna
result
pcr
would
expect
neg
clinic
sampl
limit
viral
content
ideal
sampl
taken
viraem
phase
viral
concentr
highest
sensit
sispa
depend
characterist
clinic
sampl
properti
viru
question
amount
nucleic
acid
use
sispa
experi
vari
greatli
exampl
cycl
amplif
fg
bacteriophag
gener
suffici
amplicon
visibl
agaros
gel
comparison
suffici
fulllength
cdna
sispa
gener
ng
dsrna
group
c
rotaviru
genom
segment
extract
stool
sampl
matsui
cowork
prepar
cdna
mg
nucleic
acid
isol
g
infecti
stool
sampl
estim
contain
virion
particl
per
gram
vreed
et
al
clone
littl
ng
viral
dsrna
use
sispa
pcr
cycl
virusdiscoverycdnaaflp
vidisca
figur
base
principl
sispa
use
two
primer
rather
one
pcr
amplif
step
done
amplifi
fragment
length
polymorph
aflp
techniqu
describ
dna
digest
two
frequent
cut
restrict
enzym
exampl
msei
hinpii
four
base
pair
recognit
site
produc
dna
molecul
msei
overhang
either
end
well
mseimsei
overhang
msei
fragment
amplifi
subsequ
pcr
adapt
bind
one
specif
end
dna
fragment
accord
complementari
overhang
two
primer
specif
adapt
use
exponenti
amplif
reaction
pcr
second
select
nest
pcr
amplif
use
simplifi
result
pcr
product
dna
smear
specif
band
extend
end
primer
one
three
nucleotid
subset
pcr
product
gener
differ
possibl
primer
combin
primer
extend
one
nucleotid
ie
n
n
use
two
adapt
primer
also
nest
pcr
step
make
vidisca
sensit
specif
sispa
anoth
sispa
variat
devis
vreed
et
al
adapt
lambden
clark
method
shown
figur
variat
allow
fulllength
copi
dsrna
segment
kb
size
african
hors
sick
viru
ahsv
genom
clone
basi
method
use
primer
tail
cdna
synthesi
could
initi
oligo
dt
primer
whole
genom
segment
copi
result
clone
genom
segment
sequenc
express
vitro
method
develop
onetub
reaction
could
perform
adapt
ligat
cdna
synthesi
pcr
amplif
reduc
number
pcr
cycl
use
cycl
compar
method
minimum
ng
dsrna
need
clone
complet
genom
modif
sispa
includ
incorpor
carrier
mrna
may
especi
help
tri
synthesis
cdna
pg
amount
mrna
addit
carrier
mrna
ng
shown
increas
figur
anchor
primer
use
vidisca
method
start
templat
convert
dsdna
indic
figur
digest
two
restrict
enzym
exampl
msei
two
anchor
adapterlink
prepar
anneal
togeth
top
bottom
strand
oligonucleotid
ligat
onto
digest
dsdna
fragment
first
pcr
eg
cycl
done
two
primer
msei
respect
second
pcr
perform
primer
sequenc
except
addit
n
primer
combin
second
pcr
may
done
input
ml
first
reaction
use
touchdown
condit
van
der
hoek
et
al
enrich
system
devis
use
adapt
biotinstreptavidin
captur
system
direct
select
cdna
amplifi
also
sequenceindepend
amplif
dna
use
molecular
clone
specif
microdissect
dna
chromosom
region
final
common
epitop
region
enterovirus
identifi
sispa
follow
immunoscreen
amplifi
fragment
length
polymorph
aflp
dna
fingerprint
techniqu
essenti
procedur
vidisca
prior
amplif
dna
digest
restrict
enzym
follow
ligat
doublestrand
adapt
termini
dna
fragment
like
vidisca
select
amplif
achiev
use
primer
extend
restrict
fragment
amplifi
fragment
primer
extens
match
nucleotid
flank
restrict
site
use
method
subset
restrict
fragment
may
visualis
pcr
without
prior
knowledg
nucleotid
sequenc
aflp
use
gener
mrna
fingerprint
polyploid
crop
plant
identifi
delet
chromosom
also
use
phylogenet
analysi
bacillu
anthraci
escherichia
coli
random
pcr
rpcr
techniqu
similar
sispa
use
first
primer
end
uniqu
eg
nucleotid
univers
sequenc
contain
restrict
enzym
site
subsequ
clone
follow
degener
hexaor
heptam
sequenc
end
figur
subsequ
pcr
amplif
step
carri
second
specif
primer
complementari
univers
region
first
random
primer
remov
need
adapt
ligat
step
render
sispa
ineffici
random
pcr
use
detect
dna
rna
viral
genom
random
pcr
shown
amplifi
littl
fg
phage
rna
two
copi
human
chromosom
dna
microdissect
human
chromosom
materi
also
amplifi
random
pcr
primer
random
pentam
rather
hexaor
heptam
end
detect
mouthwash
sampl
patient
chronic
fatigu
syndrom
use
random
pcr
also
use
recov
caliciviru
rna
techniqu
rda
combin
subtract
hybridis
gene
amplif
detect
differ
figur
random
pcr
random
pcr
use
amplifi
dna
rna
viral
genom
primer
uniqu
end
sequenc
indic
wavi
line
fulli
degener
end
sequenc
use
pcr
reaction
amplifi
viral
dna
usual
lower
anneal
temperatur
touchdown
condit
use
degener
part
primer
anneal
complementari
dna
sequenc
occur
stochast
throughout
viral
genom
primer
extend
use
polymeras
gener
doubl
strand
sequenc
separ
denatur
complementari
sequenc
hybridis
form
finit
portion
dsdna
first
primer
present
end
shown
darker
line
diagram
primer
repres
uniqu
sequenc
first
primer
use
subsequ
amplif
fragment
target
stang
et
al
sequenceindepend
genom
ampli
sequenceindepend
genom
amplifi
ficat
cation
enc
two
similar
clinic
sampl
virolog
like
sampl
compar
preand
postinfect
sampl
dna
isol
preinfect
sampl
act
driver
compar
dna
isol
postinfect
sampl
tester
two
dna
sampl
hybridis
togeth
reduc
common
sequenc
leav
mainli
viral
sequenc
downstream
analysi
figur
show
genom
complex
reduc
sampl
restrict
enzym
digest
follow
adapt
ligat
restrict
fragment
tester
dna
two
digest
dna
sampl
combin
heat
melt
doublestrand
cool
allow
strand
anneal
back
togeth
complementari
sequenc
tester
driver
dna
sampl
hybridis
togeth
uniqu
tester
dna
sequenc
hybridis
end
dna
fragment
fill
primer
complementari
adapt
sequenc
use
pcr
amplif
heterogen
anneal
testerdriv
fragment
undergo
linear
amplif
one
adapt
sequenc
tester
dna
strand
uniqu
reanneal
tester
homogen
fragment
undergo
exponenti
amplif
two
adapt
sequenc
tester
dna
strand
homogen
reanneal
driver
dna
fragment
adapt
sequenc
amplifi
remain
singlestrand
dna
fragment
digest
mung
bean
nucleas
specif
singlestrand
dna
use
newli
enrich
tester
amplicon
start
materi
round
subtractionamplif
procedur
repeat
sever
time
suffici
enrich
way
tester
amplicon
either
clone
librari
construct
use
probe
sourc
librari
screen
sequenc
directli
two
highli
match
nucleic
acid
sourc
necessari
success
recoveri
differ
product
sever
limit
use
rda
also
amplif
sequenc
dna
need
occur
equal
well
guarante
dna
amplifi
separ
tube
howev
rda
use
identifi
gamma
herp
viru
hepat
g
viru
anelloviru
torqu
teno
viru
ttv
balanc
pcr
method
involv
pcr
amplif
dna
sampl
one
tube
describ
claim
elimin
differ
pcr
amplif
effici
tester
driver
sampl
hu
et
al
describ
modifi
rda
method
identif
unknown
viral
agent
larg
quantiti
cdna
made
univers
longpcr
method
nestedpcrbas
subtract
hybridis
remov
singlestrand
dna
use
give
popul
dna
could
clone
give
cdna
librari
hepat
c
viru
use
control
tester
sampl
valid
system
success
found
cdna
librari
june
howev
could
find
refer
use
method
discoveri
new
viru
anoth
method
describ
pathogen
discoveri
involv
highthroughput
sequenc
cdna
librari
made
infect
tissu
recombin
cdna
librari
rna
prepar
posttranspl
lymphoprolif
disord
tissu
sampl
sequenc
obtain
clone
compar
human
genom
sequenc
comput
blast
search
match
human
genom
investig
sequenc
cdna
librari
transcript
transcript
identifi
nonhuman
proven
ebv
although
awar
method
use
discov
novel
virus
noteworthi
highthroughput
shotgun
sequenc
use
identifi
novel
microorgan
sequenc
seawat
biofilm
method
use
two
shotgunsequenc
studi
could
appli
context
includ
associ
viral
diseas
differenti
display
dd
power
method
use
investig
gene
express
specif
look
differ
express
mrna
two
close
relat
sampl
context
infecti
diseas
might
preand
postvir
infect
specimen
rna
healthi
tissu
rna
diseas
tissu
rna
extract
sourc
figur
represent
differ
analysi
rda
two
dna
sourc
need
tester
driver
differ
tester
contain
pathogen
sequenc
driver
driver
use
higher
concentr
tester
drive
reaction
dna
sampl
digest
restrict
enzym
eg
dpni
linkeradapt
provid
primer
sequenc
pcr
ad
tester
dna
digest
two
dna
popul
mix
heat
anneal
form
three
kind
molecul
testertest
sequenc
hybrid
tester
driver
driverdriv
sequenc
excess
driver
dna
testertest
molecul
enrich
pathogen
sequenc
tester
nonpathogen
sequenc
hybridis
correspond
driver
sequenc
end
reanneal
dna
fill
amplifi
pcr
primer
specif
linkeradapt
sequenc
testertest
molecul
pathogen
sequenc
preferenti
exponenti
amplifi
nucleas
digest
use
remov
unwant
ssdna
pcr
perform
round
procedur
may
carri
combin
result
pathogenenrich
differ
amplicon
excess
driver
dna
restrict
enzym
fragment
lisitsyn
et
compar
separ
revers
transcrib
oligo
dtprimer
c
g
base
end
aagc
end
cdna
reaction
use
templat
pcr
oligo
dtprimer
primer
random
sequenc
reaction
carri
presenc
radiolabel
datp
becom
incorpor
pcr
amplicon
pcr
amplicon
separ
electrophoresi
denatur
polyacrylamid
gel
visualis
autoradiographi
assum
addit
band
amplifi
rna
infect
tissu
deriv
viral
mrna
picornaviru
infect
honeybe
identifi
way
dd
compar
mrna
express
brain
aggress
worker
brain
nurs
bee
forag
worker
found
infect
picornaviru
suggest
caus
aggress
behaviour
sequenceindepend
amplif
mean
identif
viral
nucleic
acid
unknown
sequenc
also
low
concentr
clinic
sampl
may
harbour
molecul
unknown
genom
viral
nucleic
acid
sequenceindepend
amplif
may
suffici
sensit
reveal
problem
aris
gener
pcr
amplif
method
use
gener
primer
much
less
sensit
method
use
sequencespecif
primer
overcom
problem
method
amplif
nucleic
acid
appli
sampl
suffici
enrich
viral
nucleic
acid
previous
describ
prior
carri
sequenceindepend
amplif
method
techniqu
call
whole
genom
amplif
wga
method
includ
multipl
displac
amplif
mda
omniplex
amplif
degener
oligonucleotid
prime
pcr
doppcr
primer
extens
preamplif
pcr
peppcr
sever
method
avail
amplifi
whole
genom
use
one
may
mda
avail
commerci
kit
ge
healthcar
uk
ltd
littl
chalfont
uk
dna
clinic
sampl
directli
amplifi
use
mda
without
need
prior
purif
mda
exploit
high
process
bacteriophag
polymeras
gener
product
kb
size
figur
amplif
occur
stranddisplac
random
exonucleas
resist
hexam
hour
isotherm
incub
c
polymeras
error
rate
nucleotid
compar
well
taq
polymeras
error
rate
nucleotid
one
signific
properti
mda
larg
fragment
amount
dna
gener
one
step
dna
use
round
reamplif
yield
dna
consist
repres
whole
genom
demonstr
singl
nucleotid
polymorph
assay
compar
genom
hybridis
contradictori
report
amount
start
dna
need
success
mda
reaction
barker
et
al
claim
consist
dna
yield
observ
regardless
amount
start
materi
amplif
achiev
dean
et
al
suggest
copi
human
genom
dna
gener
mg
product
like
barker
claim
clinic
sampl
differ
qualiti
concentr
produc
similar
reproduc
yield
mda
contrast
lovmar
et
al
report
success
amplif
depend
amount
start
materi
recommend
use
ng
genom
equival
omniplex
anoth
wga
method
also
avail
commerci
kit
sigmaaldrich
com
pani
ltd
pool
uk
genom
dna
randomli
fragment
gener
restrict
size
rang
product
bp
convert
librari
inher
amplifi
dna
molecul
highfidel
polymeras
use
gener
amplif
amplif
monitor
realtim
like
mda
gener
reproduc
amplif
across
genom
main
advantag
omniplex
method
use
degrad
intact
dna
result
dna
product
archiv
repeatedli
reamplifi
two
method
whole
genom
amplif
doppcr
peppcr
initi
design
amplif
singl
haploid
cell
preimplant
genet
diseas
diagnosi
caveat
method
howev
gener
nonspecif
amplif
artefact
short
unus
product
incomplet
coverag
whole
genom
method
use
degener
pcr
primer
could
lead
artifici
sequenc
occur
amplif
product
whole
mrna
amplif
also
possibl
sever
commerci
kit
avail
involv
seri
enzymat
reaction
result
linear
amplif
base
antisens
rna
arna
amplif
method
first
describ
van
gelder
eberwin
develop
amplifi
label
exceedingli
small
amount
mrna
hybridis
microarray
usual
gene
express
studi
unlik
exponenti
rna
amplif
method
rtpcr
arna
amplif
maintain
represent
start
mrna
popul
procedur
begin
total
poli
rna
revers
transcrib
use
primer
contain
oligo
dt
rna
polymeras
promot
sequenc
figur
firststrand
synthesi
reaction
treat
rnase
h
cleav
mrna
small
fragment
small
rna
figur
rna
amplif
procedur
rna
amplif
achiev
make
dsdna
templat
target
transcrib
ssrna
copi
oligo
dt
promot
site
primer
use
initi
cdna
synthesi
mrna
enzym
revers
transcriptas
result
hybrid
cdna
rna
digest
rnase
h
rna
fragment
serv
primer
second
strand
cdna
synthesi
use
dna
polymeras
doublestrand
cdna
purifi
act
templat
vitro
transcript
use
rna
polymeras
gener
cdna
promot
site
incorpor
dsdna
serv
initi
site
rna
polymeras
result
antisens
amplifi
rna
purifi
downstream
applic
fragment
serv
primer
secondstrand
synthesi
reaction
produc
doublestrand
cdna
templat
transcript
contamin
rrna
mrna
fragment
primer
remov
cdna
templat
use
vitro
transcript
reaction
produc
linearli
amplifi
arna
one
advantag
sequenceindepend
amplif
cultur
independ
howev
elimin
possibl
first
inocul
specimen
cell
cultur
see
cpe
observ
may
assum
due
growth
unknown
viru
would
henc
provid
mean
amplifi
genom
even
absenc
cpe
viral
growth
may
occur
way
exampl
order
characteris
nasopharyng
aspir
specimen
inocul
onto
cynomolgu
monkey
kidney
cell
human
fetal
lung
fibroblast
hela
cell
cytopath
effect
detect
exclus
monkey
kidney
cell
pronounc
cpe
observ
passag
onto
anoth
monkey
kidney
cell
line
vidisca
appli
supernat
cultur
subsequ
identifi
specif
pcr
design
confirm
presenc
cell
cultur
clinic
sampl
use
diagnost
pcr
clinic
sampl
one
seri
experi
supernat
posit
viru
cultur
use
develop
random
pcr
protocol
protocol
valid
use
mouth
wash
sampl
patient
suffer
chronic
fatigu
syndrom
clinic
sampl
creat
cpe
hela
cell
clone
sequenc
shown
present
novel
cell
line
develop
may
use
growth
unknown
virus
includ
semidifferenti
stem
cell
cell
defici
interferon
signal
lack
transcript
factor
signal
transduc
activ
transcript
transgen
mice
may
also
use
support
growth
novel
pathogen
major
virus
discov
sequenceindepend
amplif
characteris
clone
sequenc
pcr
amplicon
use
blast
program
phylogenet
analysi
analys
sequenc
data
key
approach
howev
unknown
virus
homolog
known
virus
present
databas
nevertheless
proven
possibl
identifi
virus
distantli
relat
known
virus
exampl
novel
parvovirus
bocaviru
specif
programm
develop
analysi
sequenc
data
defin
sourc
exampl
bacteriophag
sequenc
data
phage
commun
contig
spectrum
phacc
programm
webbas
tool
design
predict
viral
commun
structur
divers
use
sequenc
contig
gener
viral
shotgun
librari
sequenc
data
mathemat
analys
increas
understand
viral
ecolog
popul
dynam
exampl
phacc
use
verifi
phage
biodivers
greater
previous
observ
commun
knowledg
programm
design
calcul
human
virus
wang
et
al
design
comprehens
dna
microarray
viral
discoveri
sequenc
recoveri
secondgener
dna
microarray
consist
oligonucleotid
deriv
everi
fulli
sequenc
refer
viral
genom
genbank
august
maximis
probabl
characteris
unknown
unsequenc
member
exist
famili
highli
conserv
viru
select
mean
number
ten
chosen
viru
total
approxim
oligonucleotid
virus
panvir
array
use
part
global
effort
identifi
novel
coronaviru
sarscov
associ
sever
acut
respiratori
syndrom
sar
prior
identif
viru
cultur
vero
cell
patient
suffer
sar
total
nucleic
acid
purifi
cultur
amplifi
hybridis
array
characteris
viru
approxim
kb
viral
genom
clone
sequenc
physic
recov
viral
sequenc
hybridis
individu
array
element
addit
random
pcr
amplif
strategi
develop
order
amplifi
viral
nucleic
acid
identifi
use
microarray
test
use
human
respiratori
specimen
multipl
virus
detect
viral
specif
microarray
report
pcr
amplicon
sequenceindepend
amplif
reaction
could
match
identifi
boriskin
et
al
develop
highresolut
lowdens
diagnost
dna
microarray
specif
central
nervou
system
viral
infect
utilis
detect
multiplex
pcramplifi
virus
csf
noncsf
specimen
array
contain
gene
target
viral
caus
mening
enceph
test
use
clinic
specimen
clinic
sensit
specif
neg
posit
predict
valu
determin
respect
result
test
compar
singl
viru
pcr
howev
boriskin
et
al
report
interpret
neg
result
difficult
affect
assay
sensit
low
viral
genom
number
samplespecif
inhibit
array
describ
includ
oligonucleotid
microarray
rapid
detect
serotyp
acut
respiratori
diseaseassoci
adenovirus
dna
probe
array
simultan
identif
herpesvirus
enterovirus
flavivirus
arraybas
pathogen
chip
develop
detect
viral
rna
dna
relev
patholog
central
nervou
system
open
read
frame
highli
conserv
heterogen
sequenc
region
within
viral
famili
use
design
total
uniqu
oligonucleotid
repres
approxim
pathogen
viral
gene
repres
differ
stage
pathogen
infect
also
put
chip
potenti
characteris
stage
viral
infect
array
test
six
postmortem
brain
sampl
human
cmv
hsv
detect
microarray
consist
comprehens
encompass
set
sequenc
probe
much
promis
viru
characteris
provid
viral
dna
rna
present
specimen
amplifi
label
multiplex
gener
consensu
pcr
method
describ
review
provid
suffici
homolog
known
viral
sequenc
rey
et
al
use
southern
blot
hybridis
quantifi
amount
viru
product
use
sispa
bovin
leukaemia
viru
cdna
preand
postsispa
analys
agaros
gel
electrophoresi
southern
blot
probe
env
gene
fragment
specif
bovin
leukaemia
viru
probe
bound
cdna
subject
sispa
detect
common
epitop
region
enterovirus
cdna
librari
construct
sispa
method
immunoscreen
use
antienteroviru
guinea
pig
antisera
antisera
patient
asept
mening
repeat
immunoscreen
immunoposit
cdna
clone
select
sequenc
clone
locat
upstream
region
koch
postul
well
known
set
criteria
fulfil
microb
proven
caus
agent
diseas
modifi
virus
river
late
sarscov
shown
fulfil
expens
infect
macaqu
monkey
arguabl
kochriv
postul
need
adapt
pathogen
identif
sequenc
discoveri
happen
howev
care
need
taken
interpret
presenc
viral
sequenc
clinic
specimen
proof
causat
diseas
obviou
strategi
follow
sequenc
discoveri
make
specif
pcr
new
viru
use
test
mani
specimen
differ
individu
diseas
control
individu
without
diseas
mani
posit
result
high
likelihood
viru
pathogen
diseas
need
conclud
remark
present
sispa
method
amplif
viral
genom
unknown
sequenc
complic
prone
amplif
sequenc
artefact
spuriou
result
method
howev
prove
worth
recoveri
previous
unknown
virus
see
tabl
reliabl
robust
reproduc
version
develop
like
find
widespread
applic
great
potenti
combin
suitabl
endstag
detect
method
microarray
high
throughput
sequenc
identif
candid
pathogen
sequenc
clinic
specimen
investig
diseas
unknown
aetiolog
standard
virolog
techniqu
neglect
favour
molecular
biolog
method
simpli
latter
thought
fashion
cell
cultur
mention
electron
microscopi
serolog
immunofluoresc
standard
pcr
test
also
use
applic
perhap
start
point
molecular
investig
diseas
unknown
aetiolog
use
pcr
consensu
primer
like
virolog
suspect
virus
may
often
identifi
protein
specif
antigenantibodi
interact
context
viru
discoveri
antibodi
shown
absent
prediseas
present
sera
patient
recov
diseas
may
diagnost
convalesc
sera
may
also
use
purifi
virus
complex
mixtur
prior
extract
amplif
genom
ambiti
may
possibl
reconstruct
recombin
antibodi
immun
cell
collect
patient
diseas
use
identifi
antigen
viru
caus
diseas
approach
demonstr
feasibl
subacut
scleros
panenceph
measl
viru
develop
multipl
sclerosi
conclus
viru
discoveri
project
exploit
convent
virolog
method
well
molecular
techniqu
amplif
unknown
sequenc
novel
cell
cultur
antibodybas
method
therefor
neglect
epidemiolog
evid
support
propos
link
diseas
studi
infecti
caus
lastli
attent
given
collect
select
satisfactori
sampl
particular
time
sampl
critic
viru
discoveri
